Clinical significance of annexin A2 heterotetramer in sepsis
Blood Vessels, Thrombosis & Hemostasis · 2026-11 · 3 (4) · 100196
DOI: 10.1016/j.bvth.2026.100196 ↗Kurz gefasst
Leserbrief in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-11. Verfasst von Hana I Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Sepsis
Abstract (Originalsprache)
We appreciate the comment from Waisman 1 that our demonstration of proteolysis of annexin A2 and loss of cell-surface fibrinolytic activity in human sepsis 2 is compelling and has potential clinical significance. Our work highlights the role of the cell-mediated fibrinolytic system beyond its established function in thrombosis and hemostasis. Immunothrombosis and thromboinflammation are increasingly being recognized as important pathophysiological mechanisms underlying the clinical sequelae observed across human immune, inflammatory, and infectious diseases. Although not the primary subject of our study, identification of potential plasminogen binding sites within the annexin A2 het-erotetrameric complex by other groups is part of the published record, and all are entitled to their interpretation. However, as the author of this letter concedes, whether plasminogen binds to K308-R309, S100A10, or both does not alter the potential clinical and therapeutic impact of our findings because loss of either of the binding sites resulting from proteolysis of annexin A2 would likely lead to loss of cell-surface fibrinolytic activity, microvascular thrombosis, and diffuse organ failure. Preservation of annexin A2 by inhibiting the relevant sepsis-associated protease would have the same therapeutic benefit in each of these scenarios. A more comprehensive understanding of the dynamics of assembly of the annexin A2 heterotetrameric complex will be essential to developing therapies that target this pathway, with the potential to prevent the downstream effects of immunothrombosis and thromboin-flammation in clinical practice.
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY.
- Department of Pediatrics, Weill Cornell Medicine, New York, NY.
Zitieren
APA
Lim, H. I., & Hajjar, K. A. (2026). Clinical significance of annexin A2 heterotetramer in sepsis. Blood Vessels, Thrombosis & Hemostasis, 3(4), 100196. https://doi.org/10.1016/j.bvth.2026.100196
Vancouver
Lim HI, Hajjar KA. Clinical significance of annexin A2 heterotetramer in sepsis. Blood Vessels, Thrombosis & Hemostasis. 2026;3(4):100196. doi:10.1016/j.bvth.2026.100196
BibTeX
@article{Lim2026,
author = {Lim, Hana I and Hajjar, Katherine A},
title = {Clinical significance of annexin A2 heterotetramer in sepsis},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2026},
volume = {3},
number = {4},
pages = {100196},
doi = {10.1016/j.bvth.2026.100196}
}
EUVIMED